Telephone sharing button Contact Us linkedin sharing button LinkedIn mailbox sharing button wuxivaccines@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Microbial

Microbial Services Development


Beginning from strain development to CMC dossier and regulatory support, our comprehensive end-to-end microbial platform services harness our highly-trained staff and world-class quality systems, which have continually completed multiple rigorous rounds of regulatory agency inspections. We provide expert, highly-efficient development services for vaccines produced via microbial fermentation, regardless of whether your product is nucleic acid- or protein-based. See below for more details on our one-stop service offering.

Strain Development

 

Strain development services include:

 

  • E. coli and yeast host systems
  • Expression vector construction
  • Sequence/codon optimization and signal peptide screening
  • Clone screening
  • cGMP cell banking and release testing

Drug Substance (DS) Process Development
 

Led by a team of experts, we offer batch and fed-batch, and downstream purification process development of molecules in different expression systems. This includes, but is not limited to, intracellular soluble products, inclusion bodies, and extracellular secreted products. Our multi-purpose/multi-product 2,000 m2 process development laboratories facilitate the development of nucleic acid- or protein-based vaccines, supporting IND-enabling toxicology studies, or preclinical and CMC development activities at various scales.

 

Our capabilities include:

 

  • Strain/clone selection support
  • Fermentation process development
  • Purification process development
  • Process verification for direct technical transfer
  • Non-GMP and pilot production
  • Scale-up, technical transfer and clinical manufacturing support
  • Process characterization, optimization and validation
  • IND/IMPD & BLA filing support

Formulation and Drug Product Development

 

We provide a dedicated team of highly-trained and experienced scientists capable of developing and optimizing vaccine product formulations filled into a wide variety of container and closure systems (CCS) including combination products (e.g., prefilled syringes and autoinjectors).

 

Our capabilities include:

 

  • Labs with processing and physicochemical testing ability
  • Pre-formulation and formulation development
  • Liquid, frozen liquid and lyophilized dosage form development
  • Forced degradation studies
  • Container closure selection/evaluation including vials and prefilled syringes (PFS), PFS with needle safety devices (NSD) and autoinjectors (AI)
  • Formulation of complex delivery systems including adjuvanted multivalent antigens, VLPs, lipid nanoparticles, and emulsions
  • Clinical in-use compatibility
  • Adjuvant selection and evaluation
  • Process scale-up, technology transfer and process performance qualification

Analytical Development

 

The analytical method development team supports many CMC activities including:

 

  • Development of in-process, release and stability-indicating methods
  • Product characterization (biochemical, biophysical, biological); comparability assessment
  • Forensic and analytical investigation; troubleshooting of GMP manufacturing-related investigations
  • Lot release and stability studies of non-GMP batches
  • Reference standard generation and characterization
  • Technology transfer to quality control (QC)
Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?